Tempest acquires rights to experimental myeloma treatment

Deal follows promising early results from ongoing Phase 1 trial

Written by Marisa Horak, MS |

Two people shake hands over a signed agreement sitting on a table.

Tempest Therapeutics has exercised an option to obtain rights to develop and commercialize an experimental therapy for myeloma. (Photo from iStock)

Following positive early data from an ongoing clinical trial, Tempest Therapeutics has exercised an option to obtain rights to develop and commercialize an experimental therapy for myeloma that is being developed by Hebei Senlang Biotechnology.

The newly executed option gives Tempest rights to the therapy, which the company is renaming TPST-4903, in all countries outside of China. The deal also gives Tempest similar rights to other experimental therapies that Senlang is developing.

“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program,” Matt Angel, PhD, president and CEO of Tempest, said in a company press release.

Recommended Reading
Various types of oral and infused or injected medications are shown.

Under-the-skin myeloma treatment linked to better survival in study

TPST-4903 designed to target and kill cancer cells

Myeloma is a form of blood cancer that occurs when immune cells called plasma cells grow out of control in the bone marrow. TPST-4903 is an in vivo CAR T-cell therapy designed to kill these cancer cells.

T-cells are immune cells that act as the body’s assassins, killing other cells that have become infected or cancerous. In CAR T-cell therapy, these cells are modified to equip them with a human-made receptor protein called a CAR (chimeric antigen receptor), which acts like a wanted poster directing these killer immune cells to more effectively target cancer cells. The CAR used in TPST-4903 is designed to simultaneously target BCMA and GPRC5D, two proteins expressed by myeloma cells.

There are a few CAR T-cell therapies for myeloma currently available, but all of them are ex vivo — meaning a patient’s T-cells need to be collected and taken to a lab for engineering, then infused back into the patient. By contrast, an in vivo CAR T-cell therapy such as TPST-4903 is designed to modify T-cells within a patient’s body, eliminating the time-consuming step of taking cells to a lab and back. The therapy delivers its genetic payload via a viral vector, which is a virus engineered to deliver therapeutic genes rather than cause infection.

We are encouraged by the emerging clinical data from the ongoing DELIVER-1 Phase 1 dose-escalation study of TPST-4903, which includes multiple myeloma patients with a substantial unmet need for new treatment options.

An investigator-sponsored Phase 1 study called DELIVER-1 (NCT07586709) is currently testing TPST-4903 in people with myeloma that remains inadequately controlled following at least two prior lines of treatment. The trial is recruiting participants at a site in Beijing.

Tempest’s decision to acquire rights for TPST-4903 was based on early data from the Phase 1 trial. These data covered 13 patients, including individuals who had previously received other CAR T-cell therapies and those with extramedullary disease (that is, myeloma tumors outside the bone marrow). According to Tempest, the early data show encouraging clinical activity and tolerability, warranting further development of the experimental therapy.

“We are encouraged by the emerging clinical data from the ongoing DELIVER-1 Phase 1 dose-escalation study of TPST-4903, which includes multiple myeloma patients with a substantial unmet need for new treatment options, such as those with extramedullary disease and those previously treated with CAR-T therapy. We look forward to sharing the detailed results with the scientific community,” Angel said.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.